Cannabis News

Aion Therapeutic Provides Notice of Default

Aion Therapeutic Inc. (CSE: AION) (" Aion Therapeutic " or the " Company ") announces that it anticipates being late in filing its audited annual financial statements (the " Annual Financial Statements ") and related management discussion and analysis (" MD&A ") for the year ended April 30, 2021 by the prescribed deadline of August 30, 2021 and its interim financial statements (the " Interim Financial Statements ") and related MD&A for the interim period ended July 31, 2021 by the prescribed deadline of September 29, 2021 .

Aion Therapeutic Inc. Logo (CNW Group/Aion Therapeutic Inc.)

During the year ended April 30, 2021 , the Company completed the acquisition of 1196691 B .C. Ltd. d/b/a PCAI Pharma. As a result of this acquisition, the Company is delayed in providing its independent auditors with the necessary valuations and impairment testing required to gain reasonable comfort to complete and file the Annual Financial Statements and MD&A.

The Company has made an application with the applicable securities regulators under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (" NP 12-203 ") requesting that a management cease trade order be imposed in respect of the anticipated late filing rather than an issuer cease trade order. The issuance of a management cease trade order does not affect the ability of persons who have not been directors, officers or insiders of the Company to trade in their securities.

The Company anticipates that it will in a position to prepare and file the Annual Financial Statements and related MD&A on or prior to September 29, 2021 , and prepare and file the Interim Financial Statements and related MD&A on or prior to October 29, 2021 .

The Company confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the filing requirements to file the Financial Statements, the Interim Financial Statements and related MD&A within the prescribed period of time. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

About Aion Therapeutic Inc.

Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.

DISCLAIMER & READER ADVISORY

Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.

SOURCE Aion Therapeutic Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/August2021/31/c1920.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Cronos Group Announces Streamlined Operating Structure to Improve Cash Flow

Plans to Exit Existing U.S. hemp-derived CBD Operations

Intends to Launch Lord Jones ® Brand in the Canadian Adult-use Market in Q4 2023

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Speak at Bernstein's 39th Annual Strategic Decisions Conference

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at Bernstein's 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023, at 1:30PM ET.

A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
phone showing canadian competition bureau website

Cannabis Weekly Round-Up: Canadian Competition Bureau Calls for Industry Changes

The Canadian cannabis industry needs new THC limits and more relaxed promotional rules in order to thrive, a federal agency said this week in a new report. It also recommends a review of the licensing process.

Meanwhile, a leading multi-state operator enjoyed a jump in share value thanks to its most recent financial report.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

Goodness Growth Holdings and Grown Rogue International Announce Strategic Advisory Agreement

Goodness Growth engages Grown Rogue to prioritize improved quality and productivity of its cultivation operations –

– Agreement unites Grown Rogue's cultivation expertise with Goodness Growth's footprint and commitment to its customers for accessible, quality cannabis products –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Creso Pharma

Wholly-Owned Subsidiary, Mernova Medicinal Inc. Continues Strong Progress In Q2 Securing C$593,926 In New Purchase Orders During May

Creso Pharma Limited (ASX:CPH, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to provide the following update on progress through wholly-owned Canadian subsidiary, Mernova Medicinal Inc. (‘Mernova’), which has continued to achieve strong growth in purchase orders in May, as well as an extension of licenses with Health Canada and Canada Revenue Agency.

Keep reading...Show less

Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Limerick, PA

New dispensary expands patient access to medical cannabis with ribbon cutting and pop-up event

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the grand opening of a new Trulieve-affiliated medical marijuana dispensary in Limerick, PA. Located at 451 West Ridge Pike, the doors will open 9 AM on Friday, May 19 2023 with ongoing hours of 9 AM - 10 PM seven days a week.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×